Therefore, our results suggest that when lung cancer patients with EGFR mutation show increased NSE and SCC in the responsive stage of EGFR TKI, the mechanism of secondary drug resistance may be the gradual differentiation of lung adenocarcinoma into other components, rather than the acquired T790M mutation. This evidence concerns the gene EGFR and lung cancer.